GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Cytokinetics
Shares of Cytokinetics, a biotech company focused on cardiovascular disease, are extremely volatile. Their price is driven by news of clinical trials for their lead drug. The chart is a story of hopes for a new blockbuster and the constant risks inherent in biotech.
Share prices of companies in the market segment - Pharma neurology
Cytokinetics is a biopharmaceutical company specializing in the treatment of muscle-weakening diseases. We classify it in the Pharma Neurology sector. The chart below shows the overall performance of this biotech segment, not just CYTK stock.
Broad Market Index - GURU.Markets
Cytokinetics is a biopharmaceutical company focused on developing drugs to treat diseases associated with muscle weakness, particularly heart failure. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Cytokinetics' performance to assess the sector's prospects.
Change in the price of a company, segment, and market as a whole per day
CYTK - Daily change in the company's share price Cytokinetics
The volatility of Cytokinetics (CYTK), a biopharmaceutical company focused on cardiovascular and neurological diseases, is reflected in Change_Co, which is highly sensitive to clinical trial results and FDA approvals. Change_Co is a measure of the extreme volatility inherent in biopharma. This metric is critical for formulaic modeling of risks and potential in the innovative pharmaceutical sector.
Daily change in the price of a set of shares in a market segment - Pharma neurology
Cytokinetics, Incorporated is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with the performance of CYTK, which focuses on heart disease, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Cytokinetics is a biopharmaceutical company specializing in cardiovascular drugs. Cardiology is a risky area of research. The chart below illustrates the high volatility typical of the biotech sector, reflecting the stakes associated with Cytokinetics' developments.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Cytokinetics
Cytokinetics is a biotech company specializing in the treatment of cardiovascular diseases. Given the prevalence of these diseases, its developments are attracting considerable attention. Its shares are volatile and dependent on research progress, contributing to market dynamics.
Annual dynamics of market capitalization of the market segment - Pharma neurology
Cytokinetics, Incorporated is a late-stage biotech company focused on developing drugs for the treatment of cardiovascular diseases. Its stock performance is entirely dependent on clinical trial results and regulatory decisions, as is typical for the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cytokinetics is a late-stage biotech whose fate hinges on the approval and success of its cardiovascular drugs. Its stock price is completely disconnected from economic cycles. Its chart is a history of binary events: positive regulatory news can trigger a surge, while failure can lead to a collapse.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Cytokinetics
The performance of Cytokinetics, a biopharmaceutical company, depends on its R&D cycle. Monthly fluctuations on the chart reflect news about clinical trials of its cardiovascular drugs, particularly its flagship candidate, Aficimten, whose success is crucial to the company's future.
Monthly dynamics of market capitalization of the market segment - Pharma neurology
This chart reflects the dynamics of the biotech sector, particularly in cardiology. For Cytokinetics, a late-stage company, it's the backdrop. Its movements reflect investor expectations surrounding the potential approval of its drug for heart disease.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cytokinetics, Inc. is a late-stage biopharmaceutical company developing muscle activators for the treatment of cardiovascular diseases. The company's fate depends on the results of clinical trials. The broader market chart serves as a backdrop to demonstrate how news about its drugs has driven stock movements completely independent of overall sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Cytokinetics
Cytokinetics' weekly stock price is a roller coaster ride for biotech investors. The stock price reacts sharply to any news about clinical trials of cardiovascular drugs. The chart below tells the story of how science and expectations shape the value of this innovative company.
Weekly dynamics of market capitalization of the market segment - Pharma neurology
Cytokinetics shares are part of the volatile biotech sector. The entire industry often experiences ups and downs based on important scientific news or regulatory changes. The chart allows you to compare the company's weekly performance with the overall pulse of the biotech industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Cytokinetics, a biotech company whose stock moves in sync with clinical trial news, is a great way to see how its weekly fluctuations are disconnected from overall market trends. Is the company just on its own, or are the global sell-offs affecting it too?
Market capitalization of the company, segment and market as a whole
CYTK - Market capitalization of the company Cytokinetics
The Cytokinetics chart is a visualization of the risks and hopes of biotech. Its market capitalization curve reflects investor expectations for new cardiovascular drugs. Each peak or trough reflects a reaction to clinical trial data and regulatory decisions.
CYTK - Share of the company's market capitalization Cytokinetics within the market segment - Pharma neurology
Cytokinetics is a biopharmaceutical company focused on treating diseases associated with muscle weakness. Its share of the sector's market capitalization reflects investor expectations for its innovative drugs. The chart illustrates how news about clinical trials and potential regulatory approvals could dramatically alter its market share.
Market capitalization of the market segment - Pharma neurology
Cytokinetics develops drugs to treat severe diseases associated with muscle weakness. To understand the potential, one must understand the entire market. The chart below is a barometer of the neuroscience pharmaceutical sector. Its growth reflects the enormous need to treat diseases that affect millions of people.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Cytokinetics chart is a visual representation of the company's hopes for a victory over heart and musculoskeletal diseases. The company's market capitalization depends almost entirely on the progress of its myoactivator drugs. Every ups and downs on this chart reflect investors' reactions to the clinical trial data that determine its future.
Book value capitalization of the company, segment and market as a whole
CYTK - Book value capitalization of the company Cytokinetics
Cytokinetics's value lies in its scientific developments, but its book value reflects the tangible side of the business—the value of its laboratories, sophisticated research equipment, and financial reserves. The chart below illustrates how the company has grown its physical capital to support cutting-edge research.
CYTK - Share of the company's book capitalization Cytokinetics within the market segment - Pharma neurology
Cytokinetics invests in the future of medicine, and its value is embodied in its cutting-edge research centers. These laboratories are equipped with unique equipment for studying muscle biology—the physical foundation for creating new drugs. The diagram shows the company's share of these specialized tangible assets in the sector.
Market segment balance sheet capitalization - Pharma neurology
Cytokinetics is an R&D-stage biotech company whose value lies in its intellectual property, not its manufacturing facilities. The chart below reflects the capital intensity of the entire pharmaceutical sector, making its lightweight, science-focused model particularly compelling.
Book value of all companies included in the broad market index - GURU.Markets
Cytokinetics is a biotech company focused on muscle biology. Its book value is small relative to the market, but it represents concentrated scientific capital. This stake in BCap_All provides the foundation for research that could radically improve patients' quality of life.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Cytokinetics
Cytokinetics's book value is its scientific equipment. Its market capitalization, however, is the valuation of its innovative approach to treating diseases related to muscle function. The gap between these metrics is enormous, reflecting the market's expectation that a single successful drug will recoup all its material costs many times over.
Market to book capitalization ratio in a market segment - Pharma neurology
Cytokinetics develops drugs targeting muscle biology. Like many biotech companies, its tangible assets are small. This reflects the significant premium the market imposes on the company's valuation, based on the potential of its scientific developments and future drugs, rather than on its current physical assets.
Market to book capitalization ratio for the market as a whole
Cytokinetics is a biopharmaceutical company specializing in the development of drugs that affect muscle contractility for the treatment of cardiovascular diseases. Compared to average market valuations, as shown in this chart, its high premium reflects investor expectations for the potential success of its lead drug candidates.
Debts of the company, segment and market as a whole
CYTK - Company debts Cytokinetics
Cytokinetics, a biopharmaceutical company focused on muscle biology, uses debt to fund cutting-edge research. Developing innovative drugs requires significant investments in clinical trials. The company's debt dynamics mirror its investments in science, which are aimed at creating new treatments for serious diseases.
Market segment debts - Pharma neurology
Cytokinetics is focused on developing drugs for muscle diseases. The path from a scientific idea to an approved drug in biotech is long and requires hundreds of millions of dollars in clinical trials. This chart allows investors to understand the company's financial strategy: whether it relies on equity or debt to finance its development.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Cytokinetics
Cytokinetics, a biopharmaceutical company, is focused on developing drugs for muscle diseases, a long and expensive process. This chart shows the extent to which the company relies on debt financing to conduct clinical trials. This information is critical for assessing its financial stability before launching its products.
Market segment debt to market segment book capitalization - Pharma neurology
Cytokinetics is focused on developing drugs for debilitating muscle diseases. The biopharmaceutical sector requires massive investments in R&D. This chart shows the industry's total debt to equity ratio, reflecting its overall risk appetite. This provides context for understanding Cytokinetics' financial strategy in the race to develop new drugs.
Debt to book value of all companies in the market
Cytokinetics, a biopharmaceutical company, requires significant capital for research. This chart shows the overall level of debt in the market, reflecting investors' willingness to finance risk. For Cytokinetics, this provides an important context: how easy is it to raise funds for innovative but risky projects when the entire corporate sector is becoming more or less indebted?
P/E of the company, segment and market as a whole
P/E - Cytokinetics
Cytokinetics is a biopharmaceutical company focused on developing drugs to treat muscle diseases. This chart shows that the company's valuation is based not on current profits, but on the expected future success of its drugs. Any changes in this indicator are closely linked to news about clinical trials and potential drug approvals.
P/E of the market segment - Pharma neurology
The biopharmaceutical sector, where Cytokinetics operates, is characterized by high risks and potential rewards. This chart shows the average valuation for more mature companies in the industry. This provides context for understanding the future market value of Cytokinetics if its muscle disease drugs are successful.
P/E of the market as a whole
Cytokinetics is a biopharmaceutical company focused on developing drugs for the treatment of diseases associated with muscle dysfunction, particularly in cardiology. Its valuation depends almost entirely on the results of clinical trials. Overall market sentiment, reflected in this chart, is irrelevant to the company compared to a single press release about the success or failure of a trial.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Cytokinetics
Cytokinetics is focused on developing muscle-targeted drugs for the treatment of serious diseases. For a biotech company at the market launch stage, this timeline is crucial. It reflects analyst expectations for successful sales and future commercialization of its research and developments, factoring in a potential blockbuster.
%20P%2FE%20Cytokinetics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Cytokinetics&v=1772596058060 "Chart of the company's future (projected) P/E Cytokinetics")
Future (projected) P/E of the market segment - Pharma neurology
Cytokinetics is a biopharmaceutical company focused on developing drugs to treat diseases associated with muscle weakness. This chart compares its future profitability expectations with those of the biotech sector. It demonstrates the extent to which investors believe in the breakthrough potential of its research, particularly in cardiovascular disease.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-neurology&v=1772596058085 "Future (projected) P/E graph of the market segment - Pharma neurology")
Future (projected) P/E of the market as a whole
Cytokinetics is a biopharmaceutical company focused on drugs for the treatment of muscle-weakening diseases. This chart is a measure of overall market optimism. For Cytokinetics, a research-stage company, a positive backdrop is important for raising capital, but its true value is determined by scientific breakthroughs, not short-term economic cycles.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772596058123 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Cytokinetics
Cytokinetics is a biopharmaceutical company focused on developing drugs to treat diseases associated with muscle weakness. This graph reflects the financial trajectory of this innovative company: significant investments in research and clinical trials drive current results in anticipation of approval and market launch of breakthrough drugs.
Profit of companies in the market segment - Pharma neurology
Cytokinetics is a biopharmaceutical company specializing in drug development for diseases associated with muscle weakness. This is a cutting-edge field with high potential and risks. This chart shows the total revenue in the neuroscience pharmaceutical sector, reflecting the industry's overall success in developing and commercializing new drugs.
Overall market profit
Cytokinetics is a biopharmaceutical company focused on treating muscle diseases. Its value is determined primarily by the results of clinical trials. However, the economic situation, reflected in this chart, plays a significant role in raising capital. During periods of growth, investors are more willing to fund long-term, risky scientific developments.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Cytokinetics
Cytokinetics is a biotech company focused on developing drugs for muscle-weakening diseases, including heart failure. Its future depends on the success of clinical trials. Revenue forecasts are probabilistic and reflect analysts' assessments of the likelihood of bringing its drugs to market.
%20profit%20of%20the%20company%20Cytokinetics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Cytokinetics&v=1772596058221 "Graph of future (projected) profit of the company Cytokinetics")
Future (predicted) profit of companies in the market segment - Pharma neurology
Cytokinetics is a biopharmaceutical company focused on developing drugs that affect muscle contractility. This chart reflects the high risks and potential rewards of the biotech sector. Cytokinetics' future depends entirely on the success of its cardiovascular drug clinical trials, which could radically change its position.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-neurology&v=1772596058247 "Graph of future (predicted) profits of companies in a market segment - Pharma neurology")
Future (predicted) profit of the market as a whole
Cytokinetics develops drugs to treat severe diseases associated with muscle weakness. Demand for its products is driven by medical indications, not the state of the economy. However, overall market expectations, as shown in the chart, influence investor sentiment and the availability of capital needed to conduct expensive clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772596058265 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Cytokinetics
Cytokinetics is a biopharmaceutical company focused on developing drugs to treat diseases associated with muscle weakness. This chart shows how expectations from clinical trials and future sales influence the company's valuation long before significant revenue is realized. It reflects investors' faith in its scientific potential.
P/S market segment - Pharma neurology
Cytokinetics is a biopharmaceutical company specializing in muscle biology and the treatment of serious diseases. In biotech, market valuation often reflects investor confidence in future breakthroughs. The data here shows the industry average revenue valuation, allowing us to determine whether the market is pricing Cytokinetics at a premium for its unique scientific advances.
P/S of the market as a whole
Cytokinetics is a biopharmaceutical company focused on developing drugs to treat muscle diseases. Its current revenue may be negligible, but its valuation is based on the potential of future drugs. This chart shows the average market price-to-revenue ratio and clearly demonstrates the gap between actual revenue estimates and the value of biotech hopes.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Cytokinetics
Cytokinetics is a biotech company focused on developing drugs to treat diseases associated with muscle weakness, including heart failure. This chart shows investor expectations for future revenue, which are entirely dependent on the success of clinical trials and the commercial potential of its innovative drugs.
%20P%2FS%20Cytokinetics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Cytokinetics&v=1772596058426 "The graph of the company's future (projected) P/S Cytokinetics")
Future (projected) P/S of the market segment - Pharma neurology
Cytokinetics is a biopharmaceutical company focused on developing drugs to treat diseases associated with muscle weakness, particularly heart failure. This chart reflects investor expectations for the company's future revenue. It demonstrates the market's confidence in the success of its clinical trials and the commercial potential of its drugs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-neurology&v=1772596058554 "Future (projected) P/S market segment graph - Pharma neurology")
Future (projected) P/S of the market as a whole
Cytokinetics is a biopharmaceutical company focused on developing drugs to treat diseases associated with muscle weakness, including heart failure. Investors' hopes for future growth, as illustrated by this chart, are largely driven by scientific breakthroughs. Cytokinetics' success could create new treatment standards and open multibillion-dollar markets.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772596058582 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Cytokinetics
Cytokinetics is a biopharmaceutical company specializing in muscle biology. Its current revenue is generated primarily through payments from large pharmaceutical partners under joint development and licensing agreements. This chart reflects the financial revenues that enable the company to advance its drugs through clinical trials.
Sales of companies in the market segment - Pharma neurology
Cytokinetics is a biotech company focused on developing drugs to treat diseases associated with muscle dysfunction. Every step in clinical trials impacts the overall pipeline. This chart reflects the overall potential of the segment, where a breakthrough drug like Cytokinetics's could create a new multibillion-dollar market.
Overall market sales
Cytokinetics, a biopharmaceutical company focused on muscle diseases, depends on overall economic health through the healthcare financing system. Growing total revenue, as reflected in the graph, translates into higher tax revenue and corporate profits. This, in turn, allows public and private insurance programs to cover expensive innovative drugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Cytokinetics
Cytokinetics is a biopharmaceutical company focused on developing drugs that affect muscle contractility. Its future sales forecast reflects market expectations regarding the commercial potential of its drugs for the treatment of cardiovascular and neuromuscular diseases. This is a bet that its science will translate into marketable therapeutic solutions.
%20sales%20of%20the%20company%20Cytokinetics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Cytokinetics&v=1772596058749 "Schedule of future (projected) sales of the company Cytokinetics")
Future (projected) sales of companies in the market segment - Pharma neurology
Cytokinetics is a biopharmaceutical company focused on developing drugs to treat diseases associated with muscle weakness, including heart failure. This chart shows forecasts for the entire pharmaceutical industry, allowing one to assess the potential contribution of Cytokinetics' breakthrough drugs to the overall growth of the sector.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-neurology&v=1772596058770 "Schedule of future (projected) sales of companies in the market segment - Pharma neurology")
Future (projected) sales of the market as a whole
Cytokinetics, a biopharmaceutical company focused on muscle diseases, monitors this chart as an indicator of the state of the healthcare system. The overall economic growth reflected here impacts hospital and insurance company budgets, and therefore their willingness to implement and pay for the innovative treatments Cytokinetics is developing.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772596058791 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Cytokinetics
Cytokinetics is focused on developing drugs that target muscle biology to treat serious diseases. Like many biotech companies, the path to profitability is long and entails significant research expenditures. This metric reflects the company's financial health, demonstrating whether it is investing in R&D or already profitable.
Market segment marginality - Pharma neurology
Cytokinetics is a biopharmaceutical company focused on the discovery and development of drugs for the treatment of diseases associated with muscle dysfunction. This chart shows its operating profitability relative to other biotech companies. For a research-stage company, above-average profitability may be due to milestone payments from development partners.
Market marginality as a whole
Cytokinetics is focused on developing drugs to treat severe muscle diseases. This chart illustrates the average profitability of the market, but for a biotech company like CYTK, it's just the backdrop. Their story is a long journey from research to a potential breakthrough, where current losses are the price of future superprofits should they succeed.
Employees in the company, segment and market as a whole
Number of employees in the company Cytokinetics
Cytokinetics is a biopharmaceutical company focused on developing drugs for debilitating muscle diseases. This chart visualizes the growth of its research and clinical potential. The team's expansion reflects progress in drug trials and preparations for their potential market launch.
Share of the company's employees Cytokinetics within the market segment - Pharma neurology
Cytokinetics is focused on developing drugs for debilitating muscle diseases. Its greatest asset is its scientific staff. The data presented shows the percentage of all specialists in the narrow field of muscle biology and pharmacology that the company attracts, a direct indicator of its research potential and leadership in its niche.
Number of employees in the market segment - Pharma neurology
Cytokinetics is a biopharmaceutical company focused on developing drugs for the treatment of muscle diseases. Its core asset is its scientific team. This chart illustrates how the company is expanding its research and clinical trial team to advance its drug candidates, which is an indicator of progress in R&D.
Number of employees in the market as a whole
Cytokinetics is a biopharmaceutical company focused on treating muscle-weakening diseases. Its growth is driven not by the overall economic climate, but by success in clinical trials. This chart reflects the overall labor market, but it is research-intensive companies like Cytokinetics that are creating the high-tech jobs that will shape the future of medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Cytokinetics (CYTK)
Cytokinetics is a biotech company focused on treating muscle diseases. Its market capitalization is based on the potential of its scientific developments and patents. This chart shows a very high value per employee, as the market values the intellectual capital generated by a small team of scientists.
%20of%20the%20company%20Cytokinetics%20(CYTK)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Cytokinetics-CYTK&v=1772596059205 "Chart of market capitalization per employee (in thousands of dollars) of the company Cytokinetics (CYTK)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma neurology
Cytokinetics is a biopharmaceutical company specializing in muscle biology, focusing on cardiovascular disease treatment. Their entire value lies in their R&D and the potential of their drugs. This chart shows the average market capitalization per employee in the sector. It reflects how highly the market values their scientific platform and research team compared to the biotech industry average.
%20by%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-neurology&v=1772596059290 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma neurology")
Market capitalization per employee (in thousands of dollars) for the overall market
Cytokinetics is a biopharmaceutical company focused on treating diseases associated with muscle weakness. Its value lies in scientific research and clinical trials. This chart demonstrates how the market values each employee, whose intellectual contribution can lead to a blockbuster and radically change patients' lives.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772596059388 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Cytokinetics (CYTK)
Cytokinetics is a biopharmaceutical company focused on drugs for muscle diseases. As with any R&D company, this chart measures potential. It shows how effectively the team of scientists and clinicians is advancing expensive research. If one drug is successful, this metric will skyrocket, reflecting the enormous value of their intellectual work.
%20Chart%20Cytokinetics%20(CYTK)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Cytokinetics-CYTK&v=1772596059433 "Company Profit Per Employee (in thousands of dollars) Chart Cytokinetics (CYTK)")
Profit per employee (in thousands of dollars) in the market segment - Pharma neurology
Cytokinetics is a late-stage biotech company specializing in the treatment of cardiovascular diseases (heart failure). This chart shows the benchmark for "Pharma Neurology" (Biotech). In this R&D sector, the benchmark is likely *negative*. Companies burn billions on R&D and clinical trials. Profit per employee (scientist) is the future goal, should the drug be approved.
%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-neurology&v=1772596059445 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma neurology")
Profit per employee (in thousands of dollars) for the market as a whole
Cytokinetics (CYTK) is a late-stage biopharmaceutical company specializing in the development of muscle activators for the treatment of cardiovascular and neuromuscular diseases. This graph, showing average profit per employee, is important for biotech. It allows one to assess how much a sector where a handful of scientists can create a breakthrough drug outperforms the "average" labor efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772596059490 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Cytokinetics (CYTK)
Cytokinetics is a biopharmaceutical company focused on muscle biology. The graph for such a company is a story of the transition from research to sales. Zero or low numbers are typical for the R&D stage, but a sharp increase in revenue per employee would indicate a successful launch of a drug developed by a small team of scientists.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Cytokinetics-CYTK&v=1772596059516 "Sales chart per company employee Cytokinetics (CYTK)")
Sales per employee in the market segment - Pharma neurology
Cytokinetics is a biotech company specializing in muscle biology and cardiovascular disease treatment. R&D in this area requires significant investment in talented scientists. This chart shows the average revenue per employee in this segment. It's important for assessing how effectively the company is transitioning from research to commercialization of its drugs.
Sales per employee for the market as a whole
Cytokinetics is a biotech company focused on treating muscle weakness. Its value has long been rooted in its scientific development. This graph reflects productivity. While drugs are in the R&D stage, it may be low, but as they reach the market, it should rise sharply, demonstrating how a small team can generate significant revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Cytokinetics (CYTK)
Cytokinetics is a biopharmaceutical company focused on developing drugs to treat diseases that impair muscle function, particularly heart failure. This chart shows high bearish interest, typical for biotech. Investors are betting against the success of its key drug, Aficamten, in trials or doubting its market potential.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Cytokinetics-CYTK&v=1772596059714 "Short Shares Chart for the Company Cytokinetics (CYTK)")
Shares shorted by market segment - Pharma neurology
Cytokinetics is a biotech company focused on drugs for the treatment of diseases associated with muscle dysfunction. This is a narrow and risky field. This chart measures the overall skepticism in biotech. It shows how many investors are generally unconvinced of the sector's success, fearing clinical trial failures or regulatory hurdles.
Shares shorted by the overall market
Cytokinetics is a biotech focused on muscle biology (heart disease). This sector is extremely sensitive to risk appetite. When the "Short_All" chart below begins to rise, it signals investor flight from speculation. This general pessimism, visible in the indicator, threatens the funding of companies like CYTK, whose breakthroughs take years.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Cytokinetics (CYTK)
Cytokinetics is a biotech company focused on drugs for the treatment of heart muscle diseases. The stock is extremely sensitive to trial news. This chart for CYTK can soar above 70 on positive R&D data. A zone below 30 often reflects research setbacks or investor concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Cytokinetics-CYTK&v=1772596059934 "RSI 14 indicator chart for the company's stock Cytokinetics (CYTK)")
RSI 14 Market Segment - Pharma neurology
Cytokinetics (CYTK) specializes in treating diseases related to muscle function, particularly in cardiology (heart failure). Their drugs target muscle "mechanics." This chart tracks overall sentiment in the Pharmaceuticals/Neurology/Cardiology sector. It helps investors understand whether CYTK's movement is a reaction to their clinical data or whether the entire sector is overheated or oversold.
RSI 14 for the overall market
Cytokinetics is a biotech company focused on treating severe muscle diseases, including heart failure. The company lacks stable revenue, and its survival depends on successful R&D. This graph, reflecting investors' risk appetite, is critical for the company. Market panic is closing the window for raising capital needed for expensive trials.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CYTK (Cytokinetics)
Cytokinetics is a biopharmaceutical company focused on developing drugs to treat diseases associated with muscle weakness, including heart failure. This chart shows the average price target from analysts, reflecting their expectations for the clinical trials and commercial potential of CYTK's drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CYTK-Cytokinetics&v=1772596060102 "A chart showing analyst consensus forecasts for the expected stock price. CYTK (Cytokinetics)")
The difference between the consensus estimate and the actual stock price CYTK (Cytokinetics)
Cytokinetics is a biotech company specializing in the development of muscle activators. Their primary focus is the treatment of heart failure (Aficamten). This chart reflects analyst expectations for the clinical trials and potential commercial success of this blockbuster. It shows the gap between the target price and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CYTK-Cytokinetics&v=1772596060165 "A chart showing the difference between the consensus forecast and the actual stock price. CYTK (Cytokinetics)")
Analyst consensus forecast for stock prices by market segment - Pharma neurology
Cytokinetics is a biopharmaceutical company focused on developing drugs to treat diseases associated with muscle weakness, particularly heart failure. This chart shows analysts' overall expectations for the biotech sector, reflecting whether experts believe breakthroughs are possible in this complex area of medicine.
Analysts' consensus forecast for the overall market share price
Cytokinetics is a biotech R&D company focused on heart failure drugs. They're burning through cash waiting for approval. This graph, reflecting expert expectations, is their risk appetite. When the market is pessimistic, investors flee risky biotechs, making it harder for CYTK to raise capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Cytokinetics
Cytokinetics is a biotech company focused on treating muscle diseases, primarily heart disease. Their entire value proposition is built around their potential blockbuster drug, Aficamten (a treatment for hepatic vascular insufficiency). This chart is a pure indicator of biotech expectations. It aggregates clinical trial data, estimated approval chances, and the market potential of their drug.
AKIMA Market Segment Index - Pharma neurology
Cytokinetics is a biotech (R&D) company focused on muscle biology. Its bet is entirely on Aficamten, a potential blockbuster treatment for a rare heart muscle disease (HCM). This summary metric evaluates R&D. The chart shows the segment average. This benchmark: how does Cytokinetics' high-risk (but potentially breakthrough) R&D bet differentiate it from the average pharma company?
The AKIM Index for the overall market
Cytokinetics is a biotech company focused on muscle biology, primarily developing drugs for severe heart conditions. It's a high-risk scientific bet. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative story, fueled by trial news, stacks up against the backdrop of overall economic trends.
